Targeting CD73 in the tumor microenvironment with MEDI9447

References

• Linden J, Cekic C. Regulation of lymphocyte function by adenosine. Arterioscler Thromb Vasc Biol 2012; 32:2097-103; PMID:22772752; http://dx.doi.org/10.1161/ATVBAHA.111.226837
   PubMed Web of Science ®Google Scholar
• Saze Z, Schuler PJ, Hong CS, Cheng D, Jackson EK, Whiteside TL. Adenosine production by human B cells and B cell-mediated suppression of activated T cells. Blood 2013; 122:9-18; PMID:23678003; http://dx.doi.org/10.1182/blood-2013-02-482406
   PubMed Web of Science ®Google Scholar
• Jalkanen S, Salmi M. VAP-1 and CD73, endothelial cell surface enzymes in leukocyte extravasation. Arterioscler Thromb Vasc Biol 2008; 28:18-26; PMID:17962625; http://dx.doi.org/ATVBAHA.107.153130
   PubMed Web of Science ®Google Scholar
• Antonioli L, Pacher P, Vizi ES, Hasko G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013; 19:355-67; PMID:23601906; http://dx.doi.org/10.1016/j.molmed.2013.03.005
   PubMed Web of Science ®Google Scholar
• Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P et al. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA 2006; 103:13132-7; PMID:16916931; http://dx.doi.org/0605251103
   PubMed Web of Science ®Google Scholar
• Waickman AT, Alme A, Senaldi L, Zarek PE, Horton M, Powell JD. Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor. Cancer Immunol Immunother 2012; 61:917-26; PMID:22116345; http://dx.doi.org/10.1007/s00262-011-1155-7
   PubMed Web of Science ®Google Scholar
• Stagg J, Beavis PA, Divisekera U, Liu MC, Moller A, Darcy PK, Smyth MJ. CD73-deficient mice are resistant to carcinogenesis. Cancer Res 2012; 72:2190-6; PMID:22396496; http://dx.doi.org/10.1158/0008-5472.CAN-12-0420
   PubMed Web of Science ®Google Scholar
• Antonioli L, Giron MC, Colucci R, Pellegrini C, Sacco D, Caputi V, Orso G, Tuccori M, Scarpignato C, Blandizzi C et al. Involvement of the P2X7 purinergic receptor in colonic motor dysfunction associated with bowel inflammation in rats. PLoS One 2014; 9:e116253; PMID:25549098; http://dx.doi.org/10.1371/journal.pone.0116253
   PubMed Web of Science ®Google Scholar
• Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK. Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res 2015; 3:506-17; PMID:25672397; http://dx.doi.org/10.1158/2326-6066.CIR-14-0211
   PubMed Web of Science ®Google Scholar
• Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: New therapeutic approaches. Cancer Discov 2014; 4:879-88; PMID:25035124; http://dx.doi.org/10.1158/2159-8290.CD-14-0341
   PubMed Web of Science ®Google Scholar
• Leone RD, Lo YC, Powell JD. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J 2015; 13:265-72; PMID:25941561; http://dx.doi.org/10.1016/j.csbj.2015.03.008
   PubMed Web of Science ®Google Scholar
• Clancy-Thompson E, Perekslis TJ, Croteau W, Alexander MP, Chabanet TB, Turk MJ, Huang YH, Mullins DW. Melanoma induces, and adenosine suppresses, CXCR3-cognate chemokine production and T-cell infiltration of lungs bearing metastatic-like disease. Cancer Immunol Res 2015; 3(8):956-67; PMID:26048575; http://dx.doi.org/2326-6066.CIR-15-0015
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human FC fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64:700-4; PMID:18560159; http://dx.doi.org/10.1107/S0907444908007877
   PubMed Web of Science ®Google Scholar
• Rust S, Guillard S, Sachsenmeier K, Hay C, Davidson M, Karlsson A, Karlsson R, Brand E, Lowne D, Elvin J et al. Combining phenotypic and proteomic approaches to identify membrane targets in a 'triple negative' breast cancer cell type. Mol Cancer 2013; 12:11-4598-12-11; PMID:23406016; http://dx.doi.org/10.1186/1476-4598-12-11
   PubMed Web of Science ®Google Scholar
• Lesokhin AM, Callahan MK, Postow MA, Wolchok JD. On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci Transl Med 2015; 7:280sr1; PMID:25810313; http://dx.doi.org/10.1126/scitranslmed.3010274
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Glennie MJ. Agonistic CD40 antibodies and cancer therapy. Clin Cancer Res 2013; 19:1035-43; PMID:23460534; http://dx.doi.org/10.1158/1078-0432.CCR-12-2064
   PubMed Web of Science ®Google Scholar
• Platten M, von Knebel Doeberitz N, Oezen I, Wick W, Ochs K. Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors. Front Immunol 2015; 5:673; PMID:25628622; http://dx.doi.org/10.3389/fimmu.2014.00673
   PubMed Web of Science ®Google Scholar
• Rolinski J, Hus I. Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy. J Immunotoxicol 2014; 11:311-8; PMID:24495309; http://dx.doi.org/10.3109/1547691X.2013.865094
   PubMed Web of Science ®Google Scholar
• Moran AE, Kovacsovics-Bankowski M, Weinberg AD. The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol 2013; 25:230-7; PMID:23414607; http://dx.doi.org/10.1016/j.coi.2013.01.004
   PubMed Web of Science ®Google Scholar
• Allard B, Pommey S, Smyth MJ, Stagg J. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res 2013; 19:5626-35; PMID:23983257; http://dx.doi.org/10.1158/1078-0432.CCR-13-0545
   PubMed Web of Science ®Google Scholar
• Resta R, Thompson LF. T cell signalling through CD73. Cell Signal 1997; 9:131-9; PMID:9113412; http://dx.doi.org/S0898-6568(96)00132-5
   PubMed Web of Science ®Google Scholar
• Mikhailov A, Sokolovskaya A, Yegutkin GG, Amdahl H, West A, Yagita H, Lahesmaa R, Thompson LF, Jalkanen S, Blokhin D et al. CD73 participates in cellular multiresistance program and protects against TRAIL-induced apoptosis. J Immunol 2008; 181:464-75; PMID:18566412; http://dx.doi.org/181/1/464
   PubMed Web of Science ®Google Scholar
• Allard B, Turcotte M, Spring K, Pommey S, Royal I, Stagg J. Anti-CD73 therapy impairs tumor angiogenesis. Int J Cancer 2014; 134:1466-73; PMID:23982901; http://dx.doi.org/10.1002/ijc.28456
   PubMed Web of Science ®Google Scholar
• Terp MG, Olesen KA, Arnspang EC, Lund RR, Lagerholm BC, Ditzel HJ, Leth-Larsen R. Anti-human CD73 monoclonal antibody inhibits metastasis formation in human breast cancer by inducing clustering and internalization of CD73 expressed on the surface of cancer cells. J Immunol 2013; 191:4165-73; PMID:24043904; http://dx.doi.org/10.4049/jimmunol.1301274
   PubMed Web of Science ®Google Scholar
• Cekic C, Linden J. Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment. Cancer Res 2014; 74:7239-49; PMID:25341542; http://dx.doi.org/10.1158/0008-5472.CAN-13-3581
   PubMed Web of Science ®Google Scholar
• Leone RD, Lo YC, Powell JD. A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy. Comput Struct Biotechnol J 2015; 13:265-72; PMID:25941561; http://dx.doi.org/10.1016/j.csbj.2015.03.008
   PubMed Web of Science ®Google Scholar
• Fedele G, Sanseverino I, D'Agostino K, Schiavoni I, Locht C, Horenstein AL, Malavasi F, Ausiello CM. Unconventional, adenosine-producing suppressor T cells induced by dendritic cells exposed to BPZE1 pertussis vaccine. J Leukoc Biol 2015; 98:631-9; PMID:26089537; http://dx.doi.org/10.1189/jlb.3A0315-101R
   PubMed Web of Science ®Google Scholar
• Geoghegan JC, Diedrich G, Lu X, Rosenthal K, Sachsenmeier KF, Wu H, Dall'Acqua WF, Damschroder M. Inhibition of CD73 AMP hydrolysis by a therapeutic antibody with a dual, non-competitive mechanism of action. MAbs 2016; 8(3):454-67; PMID:26854859; http://dx.doi.org/10.1080/19420862.2016.1143182
   PubMed Web of Science ®Google Scholar
• Jin D, Fan J, Wang L, Thompson LF, Liu A, Daniel BJ, Shin T, Curiel TJ, Zhang B. CD73 on tumor cells impairs antitumor T-cell responses: A novel mechanism of tumor-induced immune suppression. Cancer Res 2010; 70:2245-55; PMID:20179192; http://dx.doi.org/10.1158/0008-5472.CAN-09-3109
   PubMed Web of Science ®Google Scholar
• Forte G, Sorrentino R, Montinaro A, Luciano A, Adcock IM, Maiolino P, Arra C, Cicala C, Pinto A, Morello S. Inhibition of CD73 improves B cell-mediated anti-tumor immunity in a mouse model of melanoma. J Immunol 2012; 189:2226-33; PMID:22826317; http://dx.doi.org/10.4049/jimmunol.1200744
   PubMed Web of Science ®Google Scholar
• Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I, Dikov MM, Feoktistov I. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11b+Gr1+ cells. J Immunol 2011; 187:6120-9; PMID:22039302; http://dx.doi.org/10.4049/jimmunol.1101225
   PubMed Web of Science ®Google Scholar
• Muller-Haegele S, Muller L, Whiteside TL. Immunoregulatory activity of adenosine and its role in human cancer progression. Expert Rev Clin Immunol 2014; 10:897-914; PMID:24871693; http://dx.doi.org/10.1586/1744666X.2014.915739
   PubMed Web of Science ®Google Scholar
• Beavis PA, Slaney CY, Kershaw MH, Neeson PJ, Darcy PK. Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression. Immunotherapy 2015; 7:499-512; PMID:26065476; http://dx.doi.org/10.2217/imt.15.16
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res 2015; 75:2139-45; PMID:25977340; http://dx.doi.org/10.1158/0008-5472.CAN-15-0255
   PubMed Web of Science ®Google Scholar
• Thomson LF, Ruedi JM, Glass A, Moldenhauer G, Moller P, Low MG, Klemens MR, Massaia M, Lucas AH. Production and characterization of monoclonal antibodies to the glycosyl phosphatidylinositol-anchored lymphocyte differentiation antigen ecto-5'-nucleotidase (CD73). Tissue Antigens 1990; 35:9-19; PMID:2137649
   PubMedGoogle Scholar
• Airas L, Salmi M, Jalkanen S. Lymphocyte-vascular adhesion protein-2 is a novel 70-kDa molecule involved in lymphocyte adhesion to vascular endothelium. J Immunol 1993; 151:4228-38; PMID:8409398
   PubMed Web of Science ®Google Scholar
• Airas L, Niemela J, Salmi M, Puurunen T, Smith DJ, Jalkanen S. Differential regulation and function of CD73, a glycosyl-phosphatidylinositol-linked 70-kD adhesion molecule, on lymphocytes and endothelial cells. J Cell Biol 1997; 136:421-31; PMID:9015312; http://dx.doi.org/10.1083/jcb.136.2.421
   PubMed Web of Science ®Google Scholar
• Lloyd A, Vickery ON, Laugel B. Beyond the antigen receptor: Editing the genome of T-cells for cancer adoptive cellular therapies. Front Immunol 2013; 4:221; PMID:23935598; http://dx.doi.org/10.3389/fimmu.2013.00221
   PubMed Web of Science ®Google Scholar
• Groves M, Lane S, Douthwaite J, Lowne D, Rees DG, Edwards B, Jackson RH. Affinity maturation of phage display antibody populations using ribosome display. J Immunol Methods 2006; 313:129-39; PMID:16730741; http://dx.doi.org/10.1016/j.jim.2006.04.002
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr 2008; 64:700-4; PMID:18560159; http://dx.doi.org/10.1107/S0907444908007877
   PubMed Web of Science ®Google Scholar
• Sachsenmeier KF, Hay C, Brand E, Clarke L, Rosenthal K, Guillard S, Rust S, Minter R, Hollingsworth R. Development of a novel ectonucleotidase assay suitable for high-throughput screening. J Biomol Screen 2012; 17:993-8; PMID:22522649; http://dx.doi.org/10.1177/1087057112443987
   PubMed Web of Science ®Google Scholar
• National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. 2011; PMID:21595115; http://dx.doi.org/NBK54050 [bookaccession]
   PubMedGoogle Scholar